Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.
Several studies have recently reported that hepatocellular carcinoma (HCC) occurrence does not differ between hepatitis C virus patients receiving interferon (IFN)-based and IFN-free treatments considering the patients' backgrounds. However, liver fibrosis was not directly considered in these studies. In total, 3,972 patients without a history of HCC who started IFN-based or IFN-free treatment between August 2002 and April 2017 at 30 Japanese hospitals and achieved a sustained virologic response (SVR) were included. Propensity score (PS) matching considering liver histology was performed. The median age and percentage of patients with advanced liver fibrosis (F3/4) were 58 years and 11.4% in the IFN-based group and 68 years and 18.9% in the IFN-free group. The HCC occurrence rates at 1 year and 2 years were 0.4% and 1.1% in the IFN-based group and 1.6% and 4.1% in the IFN-free group, respectively, and HCC occurrence in the IFN-free group was significantly higher than that in the IFN-based group (P<0.001). The characteristics of the HCC occurrence patterns did not differ between the two groups. After PS matching, among 764 patients, the HCC occurrence rates at 1 year and 2 years were 0.5% and 1.9% in the IFN-based group and 1.1% and 3.0% in the IFN-free group, respectively, and no significant difference was observed between the two groups (P=0.489). HCC occurrence in SVR patients does not differ between IFN-based and IFN-free treatment considering liver fibrosis stage. The degree of its progress at diagnosis does not differ between the two groups.